Blog

The latest thoughts from Medicines Law & Policy partners.

Generic lumacaftor/ivacaftor

Cystic Fibrosis Buyers Club Shows the UK Government The Way

The move by a group of parents of children with cystic fibrosis (CF) to set up a buyers club to gain access to treatments...

Dutch health insurance company Menzis takes AstraZeneca to court over patent evergreening

Today health insurance company Menzis announced  that it is taking the pharmaceutical company AstraZeneca to court over the pricing of Seroquel, a medicine...

The European Commission’s proposal on a new EU-wide compulsory licensing regime

Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London A recent international health emergency, the...

Wrapping Up 2017 – some noteworthy medicines law and policy events.

2017 was a significant year for access to medicines and other medicines policy related events. Here are a few highlights of the last 12...

New reports offer evidence for extending the WTO Decision on TRIPS to Covid-19 therapeutics...

In February 2024, the 13th World Trade Organization (WTO) Ministerial Conference will take place. WTO Members are expected to decide whether to extend the...

Advanced Purchase Agreements for Covid-19 Vaccines: Do they ensure Global Public Good?

Advanced Purchase Agreements (APAs) were part of a strategy to provide upfront financing for Covid-19 vaccines and to accelerate their development and availability. Since...

The EU proposed Covid waivers of certain TRIPS rules are mostly meaningless

Since October 2020, discussions have been ongoing at the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council about a waiver of...

Wrapping up 2025: A tumultuous year for global public health law & policy

The end of 2025, a tumultuous year for global public health, is here, and it’s time for the usually highly biased Medicines Law &...

Modifier la législation européenne pour mettre en œuvre la licence d’office en France

Selon le Dr Thierry Philip, Président de l’institut Curie, la hausse des prix des nouveaux traitements contre le cancer « est devenue intenable. » L’augmentation croissante du prix...

New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments

A new briefing paper based on Medicines Law & Policy research outlines the legal instruments available for countries seeking to access key therapeutics to...